WO2004050083A1 - Iontophoretic delivery of rotigotine for the treatment of parkinson's disease - Google Patents

Iontophoretic delivery of rotigotine for the treatment of parkinson's disease Download PDF

Info

Publication number
WO2004050083A1
WO2004050083A1 PCT/EP2003/013111 EP0313111W WO2004050083A1 WO 2004050083 A1 WO2004050083 A1 WO 2004050083A1 EP 0313111 W EP0313111 W EP 0313111W WO 2004050083 A1 WO2004050083 A1 WO 2004050083A1
Authority
WO
WIPO (PCT)
Prior art keywords
rotigotine
disease
parkinson
concentration
chloride
Prior art date
Application number
PCT/EP2003/013111
Other languages
French (fr)
Inventor
Hans-Michael Wolff
Johanna Aaltje Bouwstra
Gai Ling Li
Akhmad Kharis Nugroho
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32309357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004050083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PT02026871T priority Critical patent/PT1426049E/en
Priority to BR0316947-2A priority patent/BR0316947A/en
Priority to MXPA05005462A priority patent/MXPA05005462A/en
Priority to DE60309203T priority patent/DE60309203T2/en
Priority to DK03785652T priority patent/DK1567146T3/en
Priority to EP03785652A priority patent/EP1567146B1/en
Priority to JP2004556165A priority patent/JP2006514937A/en
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Priority to SI200330539T priority patent/SI1567146T1/en
Priority to KR1020057009547A priority patent/KR101168431B1/en
Priority to CA2505040A priority patent/CA2505040C/en
Priority to NZ540190A priority patent/NZ540190A/en
Priority to AU2003294718A priority patent/AU2003294718B2/en
Publication of WO2004050083A1 publication Critical patent/WO2004050083A1/en
Priority to IL168387A priority patent/IL168387A/en
Priority to NO20052959A priority patent/NO335491B1/en
Priority to HK05111244A priority patent/HK1079108A1/en
Priority to CY20061101696T priority patent/CY1106256T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Definitions

  • the present invention relates to an effective method for treating or alleviating symptoms of Parkinson's disease, which uses iontophoretic delivery of the dopamine receptor agonist rotigotine (INN) .
  • Parkinson's disease is believed to be primarily caused by the degeneration of dopaminergic neurons in the substantia nigra. This, in effect, results in loss of tonic dopamine secretion and dopamine-related modulation of neuronal activity in the caudate nucleus, and thus in a deficiency of dopamine in certain brain regions .
  • the resulting imbalance of neurotransmitters acetylcholine and dopamine eventually results in disease related symptoms.
  • Parkinson's disease is now considered to be a more complex disorder that involves both motor and nonmotor systems.
  • Parkinson's disease is characterized by major clinical features including tremor, bradykinesia, rigidity, dyskinesia, gait disturbances, and speech disorders. In some patients, dementia may accompany these symptoms. Involvement of the autonomic nerve system may produce orthostatic hypotension, paroxysmal flushing, problems with thermal regulation, constipation, and loss of bladder and sphincter control . Psychological disorders such as loss of motivation and depression may also accompany Parkinson's disease. Parkinson's disease is primarily a disease of middle age and beyond, and it affects both men and women equally. The highest rate of occurrence of Parkinson's disease is in the age group over ' 70 years old, where Parkinson's disease exists in 1.5 to 2.5% of that population. The mean age at onset is between 58 and 62 years of age, and most patients develop Parkinson's disease between the ages of 50 and 79. There are approximately 800,000 people in the United States alone with Parkinson's disease.
  • Parkinson's disease Early motor deficits of Parkinson's disease can be traced to incipient degeneration of nigral dopa ine-releasing cells. This neuronal degeneration produces a defect in the dopaminergic pathway that connects the substantia nigra to the striatum. As the disease progresses, refractory motor, autonomic, and mental abnormalities may develop, which implies that there is progressive degeneration of striatal receptor mechanisms.
  • Parkinson's disease The clinical diagnosis of Parkinson's disease is based on the presence of characteristic physical signs. The disease is known to be gradual in onset, slowly progressive, and variable in clinical manifestation. Evidence suggests that the striatal dopamine content declines to 20% below levels found in age-matched controls before symptoms occur.
  • L-dopa levodopa
  • Levodopa passes the blood-brain barrier as a precursor for dopamine and is then converted into dopamine in the brain.
  • L-dopa improves the symptoms of Parkinson's disease but may cause severe side effects.
  • the drug tends to lose its effectiveness after the first two to three years of treatment. After five to six years, only 25% to 50% of patients maintain improvement.
  • Dopamine receptor agonists are substances which, while structurally different from dopamine, bind to different subtypes of dopamine receptors and trigger an effect which is comparable to that of dopamine. Due to the reduced side-effects, it is advantageous when the substances selectively bind to a subgroup of dopamine receptors, i.e. the D2 receptors.
  • Rotigotine is the International Non-Proprietary Name (INN) of the compound (-) -5 , 6, 7 , 8-tetrahydro-6- [propyl- [2- (2- thienyl) ethyl] -amino] -1-naphthalenol having the structure shown below
  • R-apomorphine is the International Non-Proprietary Name (INN) of the compound (R) -5, 6, 6a, 7-tetrahydro-6-methyl-4H-dibenzoquinoline-ll, 12- diol having the structure shown below
  • Ropinirole hydrochloride A further dopamine antagonist is ropinirole hydrochloride .
  • Ropinirole (INN) is (4- [2-dipropylamina) ethyl] -1, 3-dihydro- 2H-indol-2-one) having the structure shown below
  • treatment in the context of this application is meant to designate a treatment or alleviation of the symptoms of Parkinson's disease, rather than a real causative treatment leading to a complete cure .
  • the present invention provides the use of a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/1, the composition having a pH of 4 to 6.5 for the preparation of a iontophoretic device for the treatment of Parkinson's disease.
  • Iontophoresis is the introduction of various ions into the skin by means of electricity. If compared to passive transdermal delivery, iontophoresis provides for several advantages which are useful in the treatment of Parkinson's disease :
  • iontophoretic flux is influenced by several parameters, it is crucial for achieving an optimal flux to separately optimise these parameters.
  • the rotigotine concentration may be varied in accordance with the patient ' s needs and the flux required for obtaining a therapeutic effect in the treatment Parkinson's disease. However, for a optimal performance it is preferably at least 0.5 mg/ml, more preferably 0.5 mg/ml to 3 mg/ml .
  • All chloride salts which are pharmaceutically acceptable may be employed in the composition of the invention.
  • the chloride salt is selected from NaCl, triethylammonium chloride and tributylammonium chloride . Triethylammonium chloride and tributylammonium chloride are especially preferred, because they result in higher fluxes of rotigotine.
  • the composition which is used as the donor phase of the iontophoretic device, comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/1, the donor phase has a pH of 4.5 to 5.5.
  • the present invention provides a method for the treatment of Parkinson's disease, wherein a iontophoretic device, which comprises a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/1, the composition having a pH of 4 to 6.5, is applied onto the skin of a patient in need thereof.
  • a iontophoretic device which comprises a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/1, the composition having a pH of 4 to 6.5, is applied onto the skin of a patient in need thereof.
  • Any conventional iontophoretic device may be used in the invention.
  • Such iontophoretic devices are described e.g. in V. Nair, 0. Pillai, R. Poduri , R. Panchagnula,
  • the current density employed during iontophoresis may be varied according to the patient's needs and will depend on the iontophoretic device and the composition used.
  • a suitable current may be determined by the attendant physician. In general, a suitable current density will be in the range of preferably 200 to 500 ⁇ A/cm 2 .
  • the two outer chambers contained the silver plate (anode) or silver/silver chloride (cathode) driver electrons.
  • the donor phase consisted of rotigotine solution buffered with 5 mM citrate buffer (2.1 mM sodium citrate dihydrate and 2.9 mM citric acid) .
  • Example 2 Using a similar procedure as in Example 1 and a concentration of rotigotine of 1.4 mg/ml (3.98 mM) , a pH in the donor chamber of 5, a current density of 500 ⁇ A/cm 2 , a pH in the acceptor chamber of 7.4 and a temperature of 20 °C, but substituting triethylammonium chloride (TEACl) or tributylammonium chloride (TBACl) for NaCl , the influence of the different cations on the flux was evaluated.
  • the concentration of the chloride salts in the donor solution was 70 mmol/1.
  • Example 2 Using a similar procedure and the same parameters as in Example 2, the influence of reducing the pH in the acceptor chamber from 7.4 to 6.2 was evaluated for different chloride salts.
  • the concentration of the chloride salts in the donor solution was 70 mmol/1.

Abstract

By using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 in a iontophoretic device for the treatment of Parkinson's disease, it became possible to obtain a rotigotine flux across the human stratum corneum which was higher than the one previously obtained with conventional passive diffusion systems.

Description

Iontophoretic Delivery of Rotigotine for the Treatment of
Parkinson's Disease
Description
Field of the Invention
The present invention relates to an effective method for treating or alleviating symptoms of Parkinson's disease, which uses iontophoretic delivery of the dopamine receptor agonist rotigotine (INN) .
Technical Background
Parkinson's disease is believed to be primarily caused by the degeneration of dopaminergic neurons in the substantia nigra. This, in effect, results in loss of tonic dopamine secretion and dopamine-related modulation of neuronal activity in the caudate nucleus, and thus in a deficiency of dopamine in certain brain regions . The resulting imbalance of neurotransmitters acetylcholine and dopamine eventually results in disease related symptoms. Although usually regarded as a motor system disorder, Parkinson's disease is now considered to be a more complex disorder that involves both motor and nonmotor systems. This debilitating disease is characterized by major clinical features including tremor, bradykinesia, rigidity, dyskinesia, gait disturbances, and speech disorders. In some patients, dementia may accompany these symptoms. Involvement of the autonomic nerve system may produce orthostatic hypotension, paroxysmal flushing, problems with thermal regulation, constipation, and loss of bladder and sphincter control . Psychological disorders such as loss of motivation and depression may also accompany Parkinson's disease. Parkinson's disease is primarily a disease of middle age and beyond, and it affects both men and women equally. The highest rate of occurrence of Parkinson's disease is in the age group over' 70 years old, where Parkinson's disease exists in 1.5 to 2.5% of that population. The mean age at onset is between 58 and 62 years of age, and most patients develop Parkinson's disease between the ages of 50 and 79. There are approximately 800,000 people in the United States alone with Parkinson's disease.
Early motor deficits of Parkinson's disease can be traced to incipient degeneration of nigral dopa ine-releasing cells. This neuronal degeneration produces a defect in the dopaminergic pathway that connects the substantia nigra to the striatum. As the disease progresses, refractory motor, autonomic, and mental abnormalities may develop, which implies that there is progressive degeneration of striatal receptor mechanisms.
The clinical diagnosis of Parkinson's disease is based on the presence of characteristic physical signs. The disease is known to be gradual in onset, slowly progressive, and variable in clinical manifestation. Evidence suggests that the striatal dopamine content declines to 20% below levels found in age-matched controls before symptoms occur.
Treatment of Parkinson's disease has been attempted with, inter alia, L-dopa (levodopa) , which still is the gold standard for the therapy of Parkinson's disease. Levodopa passes the blood-brain barrier as a precursor for dopamine and is then converted into dopamine in the brain. L-dopa improves the symptoms of Parkinson's disease but may cause severe side effects. Moreover, the drug tends to lose its effectiveness after the first two to three years of treatment. After five to six years, only 25% to 50% of patients maintain improvement. Furthermore a major drawback of currently utilized therapies for Parkinson's disease is the eventual manifestation of the "fluctuation syndrome", resulting in "all-or-none" conditions characterized by alternating "on" periods of mobility with dyskinesias and "off" periods with hypokinesia or akinesia. Patients who display unpredictable or erratic "on-off " phenomena with oral anti-Parkinson therapy have a predictable beneficial response to i.v. administration of L-dopa and other dopamine agonists, suggesting that fluctuations in plasma concentrations of drug are responsible for the "on- off" phenomena. The frequency of "on-off" fluctuations has also been improved by continuous infusions of the dopamine receptor agonists apomorphine and lisuride. However, this mode of administration is inconvenient. Therefore, other modes of administration providing a more constant plasma level, such as topical administration, are beneficial and have been suggested in the past .
As mentioned above, one treatment approach for Parkinson's disease involves dopamine receptor agonists. Dopamine receptor agonists (sometimes also referred to as dopamine agonists) are substances which, while structurally different from dopamine, bind to different subtypes of dopamine receptors and trigger an effect which is comparable to that of dopamine. Due to the reduced side-effects, it is advantageous when the substances selectively bind to a subgroup of dopamine receptors, i.e. the D2 receptors.
One dopamine receptor agonist which has been used to treat the symptoms of Parkinson's disease is rotigotine. It has mostly been tested in the form of its hydrochloride . Rotigotine is the International Non-Proprietary Name (INN) of the compound (-) -5 , 6, 7 , 8-tetrahydro-6- [propyl- [2- (2- thienyl) ethyl] -amino] -1-naphthalenol having the structure shown below
Figure imgf000005_0001
It has before been known to administrate rotigotine by passive transdermal therapeutic systems (TTS) . Such passive transdermal therapeutic systems for the administration of rotigotine have been described for example in WO 94/07568 and WO 99/49852. However, the rotigotine flux obtained with these passive transdermal therapeutic systems is not necessarily sufficient for all patients.
Another dopamine agonist which has been used in the treatment of Parkinson's disease is R-apomorphine . R-apomorphine is the International Non-Proprietary Name (INN) of the compound (R) -5, 6, 6a, 7-tetrahydro-6-methyl-4H-dibenzoquinoline-ll, 12- diol having the structure shown below
Figure imgf000005_0002
Several approaches to develop a system for iontophoretic administration of R-apomorphine have previously been described (see for example R. van der Geest, M. Danhof, H.E. Bodde "Iontophoretic Delivery of Apomorphine : In Vi tro Optimization and Validation", Pharm. Res. (1997), 14, 1797- 1802; M. Danhof, R. van der Geest, T. van Laar, H.E. Bodde, "An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease", Advanced Drug Delivery Reviews (1998), 33, 253- 263). However, in spite of these efforts, only concentrations at the lower end of the therapeutic concentration range of 1.4 to 10.7 ng/ml could be obtained.
A further dopamine antagonist is ropinirole hydrochloride . Ropinirole (INN) is (4- [2-dipropylamina) ethyl] -1, 3-dihydro- 2H-indol-2-one) having the structure shown below
Figure imgf000006_0001
Although the iontophoretic administration of ropinirole was considered feasible, it was only possible to obtain fluxes at the lower end of the therapeutic range (see A. Luzardo- Alvarez, M. B. Delgado-Charro, J. Blanco-Mendez, "Iontophoretic Delivery of Ropinirole Hydrochloride: Effect of Current Density and Vehicle Formulation", Pharmaceutical Research (2001), 18(12), 1714-1720).
Many patients need concentrations that are significantly higher than the ones feasible using iontophoretic delivery of apomorphine or ropinirole .
In view of the broad range of symptoms of Parkinson's disease and the differing severity, there is a strong demand for a method which allows adjusting the rotigotine flux across the skin and at the same time allows for a constant receptor stimulation of the dopamine receptors of Parkinson patients. Preferably such a system should also allow for rotigotine fluxes higher than the ones achieved by passive transdermal delivery systems. In view of the discouraging experiences with the iontophoretic delivery of apomorphine, it has been surprising that iontophoretic delivery of rotigotine could provide plasma levels of rotigotine which are not only higher than the ones of conventional passive diffusion systems but are actually in a range that allows for the delivery of pharmaceutically effective drug dosages. The results obtained by using this invention allow for a reasonable expectation that an effective treatment of Parkinson's disease can be provided. It should be understood that the term "treatment" in the context of this application is meant to designate a treatment or alleviation of the symptoms of Parkinson's disease, rather than a real causative treatment leading to a complete cure .
Summary of the Invention
The present invention provides the use of a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/1, the composition having a pH of 4 to 6.5 for the preparation of a iontophoretic device for the treatment of Parkinson's disease.
Iontophoresis is the introduction of various ions into the skin by means of electricity. If compared to passive transdermal delivery, iontophoresis provides for several advantages which are useful in the treatment of Parkinson's disease :
- it allows programming of the flux at the required therapeutic rate by adjusting the electric current, and
it permits a rapid start or termination of administration of the medication, if needed, by simply turning the iontophoretic delivery system on or off. As the iontophoretic flux is influenced by several parameters, it is crucial for achieving an optimal flux to separately optimise these parameters.
Surprisingly, it was found that using a composition having a pH of 4 to 6.5 and comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/1 in the donor chamber of the iontophoretic device, fluxes well within the therapeutic range could be achieved.
By reducing the electrolyte concentration in the donor compartment it was possible to achieve the target iontophoretic flux at lower current density or to increase the transdermal dose per area unit .
During the studies conducted to evaluate the feasibility of iontophoretic delivery of rotigotine, it was found that the solubility of rotigotine decreases when the pH is increased. However, surprisingly it was found that a therapeutically relevant rate was achieved within the pH interval of 4 to 6.5 at very low rotigotine concentrations.
To provide for an optimal flux across human stratum corneum it was also necessary to provide for a sufficient concentration of Cl" ions for the electrode reaction in the donor phase. However, while maintaining the electrode reaction the addition of chloride salts reduces the solubility of rotigotine. Thus, a concentration of chloride salts of 1 to 140 mmol/1, preferably 50 to 100 mmol/1, more preferably 60 to 80 mmol/1, proved optimal.
The rotigotine concentration may be varied in accordance with the patient ' s needs and the flux required for obtaining a therapeutic effect in the treatment Parkinson's disease. However, for a optimal performance it is preferably at least 0.5 mg/ml, more preferably 0.5 mg/ml to 3 mg/ml . All chloride salts which are pharmaceutically acceptable may be employed in the composition of the invention. In a preferred embodiment of the invention the chloride salt is selected from NaCl, triethylammonium chloride and tributylammonium chloride . Triethylammonium chloride and tributylammonium chloride are especially preferred, because they result in higher fluxes of rotigotine.
In an especially preferred embodiment of the invention the composition, which is used as the donor phase of the iontophoretic device, comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/1, the donor phase has a pH of 4.5 to 5.5.
In another aspect the present invention provides a method for the treatment of Parkinson's disease, wherein a iontophoretic device, which comprises a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/1, the composition having a pH of 4 to 6.5, is applied onto the skin of a patient in need thereof.
Any conventional iontophoretic device may be used in the invention. Such iontophoretic devices are described e.g. in V. Nair, 0. Pillai, R. Poduri , R. Panchagnula,
"Transdermal Iontophoresis. Part I: Basic Principles and Considerations" Methods Find. Exp . Clin. Pharmacol. (1999), 21 (2) , 139-151.
The current density employed during iontophoresis may be varied according to the patient's needs and will depend on the iontophoretic device and the composition used. A suitable current may be determined by the attendant physician. In general, a suitable current density will be in the range of preferably 200 to 500 μA/cm2. Example 1
In vi tro iontophoretic studies for the administration of rotigotine were carried out with three-chamber flow-through diffusion cells as described by R. van der Geest et al . (R. van der Geest, M. Danhof, H.E. Bodde, "Validation and testing of a new iontophoretic continuous flow through transport cell", J. Control. Release (1998), 51, 85-19). On both sides of the acceptor compartment human stratum corneum (SC) was situated. A dialysis membrane having a 5.000 Da cut-off was used as supporting membrane. The volume of the outer chambers was approximately 2 ml, while the volume of the acceptor compartment was 0.54 ml . The two outer chambers contained the silver plate (anode) or silver/silver chloride (cathode) driver electrons. The donor phase consisted of rotigotine solution buffered with 5 mM citrate buffer (2.1 mM sodium citrate dihydrate and 2.9 mM citric acid) .
Using this set-up, a pH in the donor chamber of 5, a current density of 500 μA/cm2, a pH in the acceptor chamber of 7.4, a temperature of 20°C and an NaCl concentration in the donor chamber of 70 mmol/1, the flux of rotigotine was measured for different drug concentrations in the donor phase.
Figure imgf000010_0001
Example 2
Using a similar procedure as in Example 1 and a concentration of rotigotine of 1.4 mg/ml (3.98 mM) , a pH in the donor chamber of 5, a current density of 500 μA/cm2, a pH in the acceptor chamber of 7.4 and a temperature of 20 °C, but substituting triethylammonium chloride (TEACl) or tributylammonium chloride (TBACl) for NaCl , the influence of the different cations on the flux was evaluated. The concentration of the chloride salts in the donor solution was 70 mmol/1.
Figure imgf000011_0001
Example 3
Using a similar procedure and the same parameters as in Example 2, the influence of reducing the pH in the acceptor chamber from 7.4 to 6.2 was evaluated for different chloride salts. The concentration of the chloride salts in the donor solution was 70 mmol/1.
Figure imgf000011_0002

Claims

Claims
1. Use of a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/1, the composition having a pH of 4 to 6.5 for the preparation of a iontophoretic device for the treatment of Parkinson's disease.
2. Use according to claim 1, wherein the concentration of rotigotine is at least 0.5 mg/ml.
3. Use according to any one of claims 1 or 2 , wherein the concentration of rotigotine is 0.5 to 3 mg/ml.
4. Use according to any one of claims 1 to 3 , wherein the chloride salt is selected from NaCl, triethylammonium chloride and tributylammonium chloride .
5. Use according to claim 4, wherein the chloride salt is triethylammonium chloride or tributylammonium chloride.
6. Use according to any one of claims 1 to 5 , wherein the concentration of the chloride salt is 60 to 80 mmol/1.
7. Use according to any one of claims 1 to 6, wherein the composition is used in the donor phase of the iontophoretic device.
8. Use according to any one of claims 1 to 7, wherein the composition in the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/1, wherein the pH of the donor phase is 4.5 to 5.5'. A method for the treatment of Parkinson's disease characterised by applying a iontophoretic device, which ■ comprises a composition comprising rotigotine and at least one chloride salt in a concentration of 1 . to 140 mmol/1, the composition having a pH of 4 to 6.5, onto the skin of a patient in need thereof.
PCT/EP2003/013111 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease WO2004050083A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
PT02026871T PT1426049E (en) 2002-12-02 2002-12-02 IONTOFORETIC ADMINISTRATION OF ROTIGOTINE FOR THE TREATMENT OF PARKINSON'S DISEASE
AU2003294718A AU2003294718B2 (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
CA2505040A CA2505040C (en) 2002-12-02 2003-11-21 Composition for iontophoretic delivery of rotigotine
DE60309203T DE60309203T2 (en) 2002-12-02 2003-11-21 IONTOPHORETIC ADMINISTRATION OF ROTIGOTIN FOR THE TREATMENT OF PARKINSON'S DISEASE
DK03785652T DK1567146T3 (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
EP03785652A EP1567146B1 (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease
JP2004556165A JP2006514937A (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
BR0316947-2A BR0316947A (en) 2002-12-02 2003-11-21 Ionophoretic release of rotigotine for the treatment of parkinson's disease
SI200330539T SI1567146T1 (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease
KR1020057009547A KR101168431B1 (en) 2002-12-02 2003-11-21 Iontophoretic Delivery of Rotigotine for the Treatment of Parkinson's Disease
MXPA05005462A MXPA05005462A (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease.
NZ540190A NZ540190A (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine and a hydrochloride salt for the treatment of Parkinson's disease
IL168387A IL168387A (en) 2002-12-02 2005-05-04 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease
NO20052959A NO335491B1 (en) 2002-12-02 2005-06-16 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
HK05111244A HK1079108A1 (en) 2002-12-02 2005-12-08 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease
CY20061101696T CY1106256T1 (en) 2002-12-02 2006-11-23 IONIPHORETIC DELIVERY OF ROTIGOTINE FOR THE TREATMENT OF PARKINSON'S DISEASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026871.0 2002-12-02
EP02026871A EP1426049B1 (en) 2002-12-02 2002-12-02 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease

Publications (1)

Publication Number Publication Date
WO2004050083A1 true WO2004050083A1 (en) 2004-06-17

Family

ID=32309357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013111 WO2004050083A1 (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease

Country Status (24)

Country Link
US (1) US7632859B2 (en)
EP (2) EP1426049B1 (en)
JP (1) JP2006514937A (en)
KR (1) KR101168431B1 (en)
CN (1) CN100333723C (en)
AT (2) ATE295726T1 (en)
AU (1) AU2003294718B2 (en)
BR (1) BR0316947A (en)
CA (1) CA2505040C (en)
CY (1) CY1106256T1 (en)
DE (2) DE60204229T2 (en)
DK (2) DK1426049T3 (en)
ES (2) ES2239196T3 (en)
HK (2) HK1065706A1 (en)
IL (1) IL168387A (en)
MX (1) MXPA05005462A (en)
NO (1) NO335491B1 (en)
NZ (1) NZ540190A (en)
PL (1) PL219696B1 (en)
PT (2) PT1426049E (en)
RU (2) RU2339372C2 (en)
SI (2) SI1426049T1 (en)
WO (1) WO2004050083A1 (en)
ZA (1) ZA200503750B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068520A2 (en) 2007-11-28 2009-06-04 Schwarz Pharma Ag Polymorphic form of rotigotine
WO2010149363A2 (en) 2009-06-26 2010-12-29 Ucb Pharma Gmbh A pharmaceutical composition
US7872041B2 (en) 2004-03-24 2011-01-18 Ucb Pharma Gmbh Use of rotigotine for treating and preventing Parkinson's plus syndrome
WO2011076879A1 (en) 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
US8283376B2 (en) 2003-12-24 2012-10-09 Ucb Pharma Gmbh Use of substituted 2-aminotetralins for preventive treatment of parkinson's disease
WO2013026547A1 (en) 2011-08-19 2013-02-28 Ucb Pharma Gmbh Rotigotine in the treatment of hemispatial neglect and other deficits following stroke
WO2014079573A1 (en) 2012-11-22 2014-05-30 Ucb Pharma Gmbh Multi-day patch for the transdermal administration of rotigotine
US11033723B2 (en) 2013-07-03 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an electronic component
US11426359B2 (en) 2014-05-20 2022-08-30 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (en) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
DE10041479A1 (en) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition for the administration of N-0923
DE10041478A1 (en) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (en) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10261696A1 (en) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
DE10334188B4 (en) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
DE10359528A1 (en) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
TWI392670B (en) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
DE202008002377U1 (en) 2008-02-20 2009-06-25 Washtec Holding Gmbh cleaning device
DE102008010223A1 (en) 2008-02-20 2009-08-27 Wash Tec Holding Gmbh cleaning device
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
PL3489227T3 (en) * 2016-07-21 2021-05-04 Shandong Luye Pharmaceutical Co., Ltd. Rotigotine behenate, and manufacturing method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996226A (en) * 1984-08-13 1991-02-26 Whitby Research, Inc. Method and compositions for treatment of parkinsonism syndrome in mammels
WO1999049852A1 (en) * 1998-03-30 1999-10-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
WO2002015903A2 (en) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Novel pharmaceutical composition for administering n-0923

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108991A (en) * 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4886545A (en) * 1986-01-31 1989-12-12 Nelson Research & Development Company Compositions comprising 1-substituted azacycloalkanes and their uses
US5142044A (en) * 1986-04-23 1992-08-25 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4801586A (en) * 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5073544A (en) * 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4917896A (en) * 1986-08-15 1990-04-17 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US5118845A (en) * 1986-09-29 1992-06-02 Whitby Research, Inc. Penetration enhancer for transdermal delivery of systemic agents
US5273757A (en) * 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
ES2032570T3 (en) * 1987-11-20 1993-02-16 Farmitalia Carlo Erba S.R.L. ANTIPARKINSON DERIVATIVES OF ERGOLINA. (RESERVATION OF ART. 167.2 CPE).
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
DE3827561C1 (en) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) * 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
DE3933460A1 (en) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts OSTROGEN-ACTIVE PLASTER
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6086905A (en) * 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
JPH06510290A (en) * 1991-08-27 1994-11-17 シグナス，インコーポレイテッド Transdermal formulation for administering prazosin
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE4301781C2 (en) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Patch containing nitroglycerin, process for its production and use
US5804214A (en) * 1993-07-08 1998-09-08 Cygnus, Inc. Monolithic matrix transdermal delivery system for delivering ketorolac tromethamine
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
ATE211655T1 (en) * 1993-09-22 2002-01-15 Hisamitsu Pharmaceutical Co IONTOPHORESIS MATRIX
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
FR2732223B1 (en) * 1995-03-30 1997-06-13 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
CN1188189C (en) * 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with estrogen
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
US6242572B1 (en) * 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE19814083C2 (en) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Process for the production of transdermal therapeutic systems using basic alkali metal salts for converting active substance salts into the free bases
DK1053043T3 (en) * 1998-05-13 2002-11-18 Cygnus Therapeutic Systems Collection units for transdermal sampling systems
DE19828273B4 (en) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing hormones and crystallization inhibitors
DE69913153D1 (en) * 1998-09-17 2004-01-08 Cygnus Therapeutic Systems DEVICE FOR COMPRESSING A GEL / SENSOR UNIT
FR2792529B1 (en) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING 2-ISOXAZOLE-8-AMINOTETRALINE DERIVATIVES
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19938823A1 (en) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol
DE19938825A1 (en) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Active ingredient combination with clonidine
DE19940238A1 (en) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Therapeutic system containing active ingredients for application to the skin with at least two polymer-containing layers
BRPI0015939B8 (en) * 1999-11-29 2021-05-25 Lts Lohmann Therapie Systeme Ag transdermal therapeutic system with improved stability and process for its preparation
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (en) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermal therapeutic system for administration of oxybutynin, especially for treatment of bladder dysfunction, having two-phase matrix layer of active agent-containing droplets dispersed in adhesive
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
WO2004000263A1 (en) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US7038085B2 (en) * 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (en) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
JP2007518754A (en) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition comprising a monoamine neurotransmitter reuptake inhibitor and a dopamine agonist
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996226A (en) * 1984-08-13 1991-02-26 Whitby Research, Inc. Method and compositions for treatment of parkinsonism syndrome in mammels
WO1999049852A1 (en) * 1998-03-30 1999-10-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
WO2002015903A2 (en) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Novel pharmaceutical composition for administering n-0923

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAAS DEN I ET AL: "TRANSDERMAL ADMINISTRATION OF THE DOPAMINE AGONIST N-0437 AND SEVEN ESTER PRODRUGS: COMPARISON WITH ORAL ADMINISTRATION IN THE 6-OHDA TURNING MODEL", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 342, no. 6, December 1990 (1990-12-01), pages 655 - 659, XP001062117, ISSN: 0028-1298 *
DANHOF M ET AL: "An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease.", ADVANCED DRUG DELIVERY REVIEWS, vol. 33, no. 3, pages 253 - 263, XP002237909, ISSN: 0169-409X *
LI G L ET AL: "Iontophoretic delivery of apomorphine in vitro: Physicochemic considerations", PHARMACEUTICAL RESEARCH 2001 UNITED STATES, vol. 18, no. 11, 2001, pages 1509 - 1513, XP001149891, ISSN: 0724-8741 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283376B2 (en) 2003-12-24 2012-10-09 Ucb Pharma Gmbh Use of substituted 2-aminotetralins for preventive treatment of parkinson's disease
US7872041B2 (en) 2004-03-24 2011-01-18 Ucb Pharma Gmbh Use of rotigotine for treating and preventing Parkinson's plus syndrome
EP2215072B1 (en) 2007-11-28 2015-09-02 UCB Pharma GmbH Polymorphic form of rotigotine
WO2009068520A2 (en) 2007-11-28 2009-06-04 Schwarz Pharma Ag Polymorphic form of rotigotine
US8592477B2 (en) 2007-11-28 2013-11-26 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production
US8232414B2 (en) 2007-11-28 2012-07-31 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production
US8754120B2 (en) 2009-06-26 2014-06-17 Ucb Pharma Gmbh Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
WO2010149363A2 (en) 2009-06-26 2010-12-29 Ucb Pharma Gmbh A pharmaceutical composition
US9034914B2 (en) 2009-06-26 2015-05-19 Ucb Pharma Gmbh Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EP3257504A1 (en) 2009-12-22 2017-12-20 UCB Biopharma SPRL Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
WO2011076879A1 (en) 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
US9925150B2 (en) 2009-12-22 2018-03-27 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
US10130589B2 (en) 2009-12-22 2018-11-20 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
US10350174B2 (en) 2009-12-22 2019-07-16 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
WO2013026547A1 (en) 2011-08-19 2013-02-28 Ucb Pharma Gmbh Rotigotine in the treatment of hemispatial neglect and other deficits following stroke
WO2014079573A1 (en) 2012-11-22 2014-05-30 Ucb Pharma Gmbh Multi-day patch for the transdermal administration of rotigotine
US11389410B2 (en) 2012-11-22 2022-07-19 Lts Lohmann Therapie-Systeme Ag Multi-day patch for the transdermal administration of rotigotine
US11033723B2 (en) 2013-07-03 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an electronic component
US11426359B2 (en) 2014-05-20 2022-08-30 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator

Also Published As

Publication number Publication date
AU2003294718B2 (en) 2008-07-31
HK1065706A1 (en) 2005-03-04
CN100333723C (en) 2007-08-29
BR0316947A (en) 2005-10-18
DE60309203T2 (en) 2007-08-23
KR20050086886A (en) 2005-08-30
US7632859B2 (en) 2009-12-15
ATE342719T1 (en) 2006-11-15
KR101168431B1 (en) 2012-07-25
EP1567146A1 (en) 2005-08-31
RU2005114749A (en) 2006-01-20
CN1720041A (en) 2006-01-11
NO20052959L (en) 2005-06-16
EP1567146B1 (en) 2006-10-18
MXPA05005462A (en) 2005-07-25
ATE295726T1 (en) 2005-06-15
IL168387A (en) 2009-05-04
SI1426049T1 (en) 2005-08-31
US20040116537A1 (en) 2004-06-17
DK1426049T3 (en) 2005-08-22
EP1426049B1 (en) 2005-05-18
ES2273062T3 (en) 2007-05-01
EP1426049A1 (en) 2004-06-09
PT1426049E (en) 2005-09-30
PL377575A1 (en) 2006-02-06
ZA200503750B (en) 2006-11-29
NZ540190A (en) 2007-03-30
PL219696B1 (en) 2015-06-30
SI1567146T1 (en) 2007-02-28
DE60204229D1 (en) 2005-06-23
HK1079108A1 (en) 2006-03-31
PT1567146E (en) 2007-01-31
DE60204229T2 (en) 2006-02-02
DE60309203D1 (en) 2006-11-30
CY1106256T1 (en) 2011-06-08
RU2478383C2 (en) 2013-04-10
NO335491B1 (en) 2014-12-22
CA2505040C (en) 2012-10-16
JP2006514937A (en) 2006-05-18
CA2505040A1 (en) 2004-06-17
AU2003294718A1 (en) 2004-06-23
ES2239196T3 (en) 2005-09-16
DK1567146T3 (en) 2007-02-19
RU2339372C2 (en) 2008-11-27
RU2008121750A (en) 2009-12-20

Similar Documents

Publication Publication Date Title
EP1426049B1 (en) Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
US9034914B2 (en) Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
US9592291B2 (en) Methods for iontophoretically treating nausea and migraine
AU2008358027B2 (en) Pharmacokinetics of iontophoretic sumatriptan administration
US10632195B2 (en) Pharmaceutical device for electric-field assisted administration of Tapentadol and method of administering Tapentadol with same
US6489356B2 (en) Method for treating pain in humans
EP1796610A2 (en) Transdermal therapeutic system for parkinson's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2005109150

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003785652

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 168387

Country of ref document: IL

Ref document number: 2505040

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200503750

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 540190

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/005462

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057009547

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038A47255

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 377575

Country of ref document: PL

Ref document number: 2004556165

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003294718

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: A20050498

Country of ref document: BY

ENP Entry into the national phase

Ref document number: 2005114749

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057009547

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003785652

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316947

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2003785652

Country of ref document: EP